The company has started the European Phase III trials of ATX-101 in 2010 in collaboration with Intendis, Bayer HealthCare’s dermatology unit, which has licensed rights to ATX-101 outside of the US and Canada.
The funding has been granted by its investors, Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco, Partner Funds management (PFM), Invus Financial Advisors, BBT Capital Management/Apothecary Capital, and Altitude Life Science Ventures.